Table 2. Summary of necroptosis in different AKI models in vivo.
| Year | Model | Possible initiating molecules | Therapeutic intervention | Effect of zVAD | Reference |
|---|---|---|---|---|---|
| 2012 | Renal ischemia/reperfusion injury | NA | Nec-1 | No effect | 47 |
| 2013 | Renal ischemia/reperfusion injury; cisplatin-induced AKI | NA | Nec-1; Rip3-KO | Protective in cisplatin-induced AKI | 51 |
| 2013 | Contrast-induced AKI | NA | Nec-1 | No effect | 58 |
| 2015 | Cisplatin-induced AKI | TNF-α, TWEAK, IFN-γ | Nec-1; Rip3-KO; Mlkl-KO | NA | 55 |
| 2015 | Cardiorenal injury after glycerol-induced rhabdomyolysis | TNF-α | Infliximab (TNF-α antibody); Nec-1 | NA | 59 |
Abbreviations: AKI, acute kidney injury; IFN, interferon; Nec-1, necrostatin-1; TNF, tumor necrosis factor; TWEAK, TNF-related weak inducer of apoptosis.